Christy Shaffer, Ph.D. – Board Chair Venture Partner and Managing Director of Hatteras Discovery Dr. Shaffer has served as a director of our company and as the chairman of our board of directors since January 2012. Since 2011, Dr. Shaffer has served as a Venture Partner with Hatteras Venture Partners, an investment firm, and as Managing Director of Hatteras Discovery, which invests in early-stage companies in the life sciences industry sector. From 1995 to March 2010, Dr. Shaffer served in increasing leadership positions at Inspire Pharmaceuticals, a publicly held biopharmaceutical company, beginning as the company’s first full-time employee and Director of Clinical Operations and eventually being appointed as Chief Executive Officer and a director of the company in 1999, as its President in 2005 and a member of its Development Committee in 2009. Prior to Inspire, she was a clinical research scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co. Dr. Shaffer currently serves in leadership roles on several non-profit boards, including as chair of the Morehead Planetarium and Science Center’s advisory board, on the Board of Trustees for the Cystic Fibrosis Foundation, and as chair of the board of CFF Therapeutic, Inc. Dr. Shaffer is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessee’s Health Science Center in Memphis, Tennessee. She completed post-doctoral training at The Chicago Medical School as well as the University of North Carolina at Chapel Hill.
Clay B. Thorp – Board Member General Partner with Hatteras Venture Partners Mr. Thorp has served as a director of our company since January 2012. In 2001, Mr. Thorp co-founded and has since served as General Partner of Hatteras Venture Partners, an investment firm, where he leads investments in a range of life science companies in the biopharmaceutical, medical device, diagnostics and research informatics sectors. Previously, he was instrumental in the founding of several life sciences companies, including serving as co-founder, Chief Executive Officer and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired by Symyx Technologies in 2005, co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc., co-founder and head of corporate development for Novalon Pharmaceutical Corporation, which was sold to Karo Bio in 2000, and co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Mr. Thorp holds a Masters of Public Policy from Harvard University and a B.A. degree in Mathematics and History from the University of North Carolina at Chapel Hill.
William D. Humphries – Board Member CEO, Merz, Inc. Mr. Humphries has served as a director of our company since January 2012. Mr. Humphries has served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company, since March 2012. From 2006 to March 2012, he served in a number of leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel from 2009 until March 2012. Before Stiefel, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business. Mr. Humphries has served on the board of ZARS Pharma, the GlaxoSmithKline Portfolio Investment Board and GlaxoSmithKline Ophthalmology Board. Mr. Humphries received his M.B.A. degree from Pepperdine University and a B.A. degree from Bucknell University.
Daniel H. White – Board Member President and CEO, Clearside Biomedical Mr. White is the founder of our company and has served as our President and Chief Executive Officer and as a member of our board of directors since our inception in May 2011. From 2008 to 2011, Mr. White served as Executive Director, Global Corporate Development, for Stiefel Laboratories, Inc., a dermatology pharmaceutical company acquired by GlaxoSmithKline in 2009. From 2007 to 2008, he co-founded and served as President and Chief Executive Officer of Percept BioScience, Inc., a biotechnology company. In 2003, Mr. White co-founded, and until 2007 served as Vice President of Finance and Corporate Development of Alimera Sciences, Inc., a biopharmaceutical company focused on ophthalmology. Previously he was Head of Business Development and Licensing for CIBA Vision, a Novartis company, and Director of Licensing and Business Development for AAIPharma. Mr. White holds an M.B.A. degree from Wake Forest University and a B.S. degree in molecular biology from Auburn University.
Evgeny Zaytsev, M.D., Ph.D., M.B.A. – Board Member Dr. Zaytsev is a venture capitalist with more than twelve years’ investment experience in life sciences. Before joining RMI Partners (the management company for RusnanoMedInvest) he was a general partner at Palo-Alto, CA-based Helix Ventures, which he co-founded to exclusively invest in novel therapeutic opportunities in biopharmaceuticals and medical devices. Prior to Helix Dr. Zaytsev was a partner of the venture capital pioneer Pitch Johnson at Asset Management Company, one of the oldest venture firms in Silicon Valley. He has been involved in more than 30 investments in biomedical companies, including such success stories of venture capital as BiPar Sciences (acquired by Sanofi-Aventis), Chimerix (NADSDAQ: CMRX), Enteric Medical Technologies (acquired by Boston Scientific), Fusion Medical Technologies (acquired by Baxter International), MicroVention (acquired by Terumo Corporation), TriVascular (acquired by Boston Scientific). He has been a Board Member of a number of companies in Silicon Valley and Russia. Dr. Zaytsev has been Chief Scientific Officer of Institute of Medico-Ecological Problems in Barnaul, Siberia, Russia, responsible for studying the health and environmental effects of the former Soviet Union’s nuclear tests. Under his leadership the Institute developed into an internationally recognized research center. Dr. Zaytsev is an active business community leader, a founder and the first president of US-Russia Technology Symposium at Stanford University (now Global Technology Symposium), and the annual Silicon Valley Open Doors investment conference. Dr. Zaytsev is an author of more than 70 scientific and business publications on entrepreneurship, venture capital and biotechnology. Evgeny Zaytsev received his M.D. (cum laude) in 1991 and his Ph.D. in physiology in 1993, both from the Altai State Medical University. He earned his M.B.A. from the Stanford Graduate School of Business in 2002.
Gerald D. Cagle, Ph.D. – Board Member Dr. Cagle has served as a member of our Board since July 2013. Dr. Cagle previously served as Chief Operating Officer at Cognoptix, lnc., a company focused on the diagnosis of Alzheimer’s disease. Dr. Cagle served as Senior Vice President of Research & Development at Alcon Laboratories lnc. from 1997 to 2008, assuming the responsibility of Chief Scientific Officer in 2006. Dr. Cagle currently serves as a member of the Board of Directors of Aerie Pharmaceuticals, a company focused on the treatment of glaucoma and other diseases of the eye, AB2 Bio, a Swiss company researching novel therapies and GrayBug Vision, focusing on ocular diseases. Dr. Cagle has served on the Wilmer Eye Institute Advisory Council and is a member of the ARVO Foundation Board of Governors. Dr. Cagle received his BS degree from Wayland College and earned both his MS and PhD degrees from the University of North Texas..
Derek Yoon – Board Member Mr. Yoon is Partner at Aju IB Investment, one of leading venture capital firms in Korea. Based in Boston, Massachusetts, Mr. Yoon oversees Aju IB’s international investments with focus on U.S. based life science companies and early stage start-ups with novel science. Mr. Yoon also leads multiple cross-border strategic partnerships by leveraging his strong relationship with top-tier pharmaceutical companies in Korea. Currently, he is also involved in multiple overseas venture capital fundraising projects by interacting with Korean governmental institutional funds as well as various private investors in Asia. Prior to joining Aju IB Investment, he spent more than fifteen years in alternative (VC/PE) investments and healthcare corporate banking where he took numerous responsibilities in portfolio management, corporate due diligence, deal structuring, fundraising and fund liquidation. His previous experience includes seven years of venture investment management at Kibo Capital, the oldest venture fund in Korea; three years of portfolio management with RBS Citizens Healthcare Banking Group; and two years with venture accelerator program at Berwind Private Equity, a multi-generational family office located in Harvard, Massachusetts. Mr. Yoon earned his M.B.A. from Babson College, M.S.F from Boston College and B.S. in Chemical Engineering from Yonsei University in Seoul, Korea.
Richard J. Croarkin – Board Member Mr. Croarkin served as the Chief Financial Officer of Nestlé Health Science S.A., a division of Nestlé focused on medicalized nutrition solutions for chronic medical conditions. Prior to this, Mr. Croarkin was Senior Vice President of Finance, Chief Financial Officer & Corporate Strategy Officer at Alcon, Inc., which was the world’s leading ophthalmic pharmaceutical and medical device company before its acquisition by Novartis in 2011. Before Alcon, Mr. Croarkin served as EVP and CFO of Nestlé Waters North America after working for Pepsico Incorporated for 11 years where he served in several global senior financial positions including Chief Financial Officer of Pepsi-Cola Latin America and Pepsi-Cola Canada. Mr. Croarkin began his career with AMAX, Inc. where he worked in treasury, corporate development and planning. He holds a BA in Economics from Georgetown University, an MBA in Finance from the University of Connecticut and a Diploma in French language from Alliance Francaise in Paris, France. Mr. Croarkin is currently a Director on the Board of Aerie Pharmaceuticals, Inc. and also serves as a panelist on the NASDAQ Listing Qualifications Panel.